Tamoxifen use in Indian women-Adverse effects revisited

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 4, 2009, Pages 609-612

  Ashraf, M ^a   Biswas, J ^a   Majumdar, S ^a   Nayak, S ^a   Alam, N ^a   Mukherjee, K K ^a   Gupta, S ^a  

^a CHITTARANJAN NATIONAL CANCER INSTITUTE   (India)

Author keywords

Adverse effects; Indian breast cancer patients; Tamoxifen

Indexed keywords

EID: 77951105236     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Agarwal G, Pradeep PV,Aggarwal V, Yip CH,Cheung PS (2007). Spectrum of breast cancer in Asian women. World J Surg, 31, 1031-40
2. Arenas M, Rovirosa A, Hernández V, et al (2006). Uterine sarcomas in breast cancer patients treated with tamoxifen. Int J Gynecol Cancer, 16, 861-5
3. Buzdar A, Howel A, Cuzio J, et al (2006). Comprehensive side effect profile of anastrazole and tamoxifen as adjuvant treatment for early stage breast cancer: Long term safety analysis of the ATAC trial. Lancet Oncol, 7, 633
4. Baraket RR (1999). The effects of tamoxifen on the endometrium. J Clin Oncol, 7, 1967-8
5. Barakat RR, Gilewski TA, Almadrones L, et al (2000). Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol, 18, 3459-63
6. Bergman L, Beelen ML, Gallee MP, et al (2000). Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet, 356, 881-7
7. Chlebowski RT (2008).Translating the data into patients' benefits: making a right choice. Breast, 17, 9-11
8. Colleoni M, Gelber S, Goldhirsch A, et al (2006).Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer. J Clin Oncol, 24, 1332
9. Fisher B, Bryant J, Dignam JJ, et al (2002). Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancer of 1 cm or less. J Clin Oncol, ??, ???
10. Fisher B, Constantino JP, Wickerham DL, et al (2005). Tamoxifen for prevention of breast cancer: current status of the National Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst, 97, 1652
11. Fotiou S, Hatjieleftheriou G, Kyrousis G, Kokka F, Apostolikas N (2000). Long term tamoxifen treatment: a possible etiological factor in the development of uterine carcinosarcoma; two case reports and review of literature. Anticancer Res, 20, 2015-20
12. Fristch M, Jordan VC (1994).Long term tamoxifen therapy for treatment of breast cancer. Cancer Control, 1, 356-66
13. Hoda D, Perez DG, Loprinzi CL, et al (2003). Hot flashes in breast cancer survivors. Breast, 9, 431-8
14. Howell A,Cuzik J,Baum M, et al (2005). Results of ATAC Trial after completion of 5 years adjuvant treatment for breast cancer. Lancet, 365, 60
15. Jussuwala DJ, Yeole BB, Natekar MV, Sunny L (1993). Cancer morbidity and mortality in Greater Bombay. Bombay Cancer registry, Bombay 1995
16. Kloos I, Delaloge S, Pautier P, et al (2002). Development of uterine sarcoma after tamoxifen treatment for breast cancer: report of a few cases. Int J Gynecol Cancer, 12, 496-500
17. Matthew P, Goetz C, Erlichman C, Loprinzi L (2008). Pharmocology of endocrine manipulation. In 'Cancer Principles and Practice of Oncology. 8th ed.vol.1, 557-8
18. Nemoto Y, Saibara T, Ogawa Y, et al (2002). Tamoxifen-induced nonalcoholic steatohepatitis in breast cancer patients treated with adjuvant tamoxifen. Intern Med, 41, 345-50
19. Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S (2003). Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol, 180, 129-34